# Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

> **NCT07178912** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Phase II Clinical Trial
- Blinatumomab
- Olverembatinib
- Lymphoblastic Leukemia
- Philadelphia Chromosome Positive

## Interventions

- **DRUG:** Blinatumomab
- **DRUG:** olverembatinib

## Key facts

- **NCT ID:** NCT07178912
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-27
- **Primary completion:** 2031-09-30
- **Final completion:** 2033-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07178912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07178912, "Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07178912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*